tirzepatide doctor Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Compound Tirzepatide For Weight Loss

Journal of inherited metabolic disease

Overweight and obesity are fundamentally consequences of excessive caloric intake, but the ever-increasing number of overweight people, despite its well-documented negative health effects, shows that restoring this imbalance is not easy, especially in our time of food abundance

We still require controlled human trials, standardized dosing, and long-term safety studies

According to the MHRA product information, the most frequently reported adverse reactions include: Nausea and vomiting : Very common (affecting more than 1 in 10 people), typically most pronounced during the first 48 weeks of treatment or following dose escalation Diarrhoea : Common (affecting up to 1 in 10 people), with frequency increasing at higher doses Abdominal pain or discomfort : Often described as cramping or bloating sensations Decreased appetite : A direct result of the medication's action on satiety centres Constipation : Less common than diarrhoea but can occur in some individuals Dyspepsia (indigestion) : Characterised by upper abdominal discomfort or burning The timing of these side effects follows a predictable pattern in most patients